Effects of incarceration on HIV-infected individuals

Journal of the National Medical Association

Volumn 88, Issue 10, 1996, Pages 639-644

  Griffin, Moya M ^b   Ryan, John G ^b   Briscoe, Victoria S ^a   Shadle, Kathleen M ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

Human immunodeficiency virus (HIV); Incarceration; Pharmaceutical intervention

Indexed keywords

ANTIVIRUS AGENT;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; EPIDEMIOLOGY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INCIDENCE; MALE; MIDDLE AGED; PRISON; RETROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PRISONS; RETROSPECTIVE STUDIES; RISK FACTORS; SAMPLING STUDIES;

EID: 0030266439     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Centers for Disease Control. The second 100,000 cases of acquired immunodeficiency syndrome-United States, June 1981-December 1991. MMWR. 1992;41:28-29.
2. Selik RM, Chu SY, Buehler JW. HIV infection as leading cause of death among young adults in US cities and states. JAMA. 1993;269:2991-2994.
3. Centers for Disease Control. Mortality attributable to HIV infection/AIDS - United States, 1981-1990. MMWR. 1991;40:41-44.
4. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. 1993;5(3): 4-5.
5. Centers for Disease Control. AIDS in Women - United States. MMWR. 1990;39:845-846.
6. Centers for Disease Control. Update: acquired immunodeficiency syndrome - 1991. MMWR. 1992;41:463-468.
7. Murphy TF. Women and drug users: the changing faces of HIV clinical drug trials. Q Rev Biol. January 1991:26-32.
8. Hansel NK, Weeks M, Ryan JG, Fowler GC. The female role in the transmission of HIV infection. Arch Fam Med. 1993;2:870-873.
9. de Bruyn M. Women and AIDS in developing countries. Soc Sci Med. 1992;34:249-262.
10. Carovano K. More than mothers and whores: redefining the AIDS prevention needs of women. Int J Health Serv. 1991;21:131-142.
11. Weisfuse IB, Greenberg BL, Back SD, Makki HA, Thomas P, Rooney WC, et al. HIV-1 infection among New York City inmates. AIDS. 1991;5:1133-1138.
12. Hoxie NJ, Vergeront JM, Frisby HR, Pfister JR, Golubjatnikov R, Davis JB. HIV seroprevalence and the acceptance of voluntary HIV testing among newly incarcerated male prison inmates in Wisconsin. Am J Public Health. 1990;80:1129-1131.
13. Dubler NN, Sidel VW. On research on HIV infection and AIDS in correctional institutions. Milbank Q. 1989;67:171-207.
14. Patel KK, Hutchinson C, Sienko DG. Sentinel surveillance of HIV infection among new inmates and implications for policies of corrections facilities. Public Health Rep. 1990;105:510-514.
15. Temple MT. Patterns of sexuality in a high-risk sample: results from a survey of new intakes at a county jail. Arch Sex Behav. 1993;22:111-129.
16. Chu SY, Peterman TA, Doll LS, Buehlar JW, Curran JW. AIDS in bisexual men in the United States: epidemiology and transmission to women. Am J Public Health. 1992;82:220-224.
17. Spillman BC. The impact of being uninsured on utilization of basic health care services. Inquiry. 1992;29:457-466.
18. Sande MA, Volberding PA, eds. The Medical Management of AIDS. Philadelphia, Pa: WB Saunders Co; 1992.
19. Houston AIDS Surveillance Update. 1993;10(2).
20. Seligmann M, Pinching AJ, Rosen FS, Fahey JL, Khaitor RM, Klatzmann D. Immunology of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Ann Intern Med. 1987;107:234-242.
21. Goedert JJ, Biggar RJ, Winn DM, et al. Determinants of retrovirus (HTLV-III) antibody and immunodeficiency conditions in homosexual men. Lancet. 1984; ii:711-715.
22. Easterbrook P, Emami J, Gazzard B. Rate of CD4 cell decline and prediction of survival in zidovuidine-treated patients. AIDS. 1993;17:960-961.
23. Yarchoan R, Thomas RV, Allain J-P, et al. Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet. 1988;i:76-81.
24. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: a double-blind placebo controlled trial. Ann Intern Med. 1990;112:727-737.
25. Lambert JS, Seidlin M, Reichman RC, et al. 2′,3′-dideoxyinosine (ddl) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. N Engl J Med. 1990;322:1333-1340.
26. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1987;317:185-191.
27. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989;243:1731-1734.
28. Centers for Disease Control and Prevention. 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults. 1993;41(RR-17):1-11.